Risk factors
Alpha Cognition (ACOG) risk factors
Item 1A of every Alpha Cognition Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks2 new1 dropped8 reworded
Alpha Cognition incurred significant net losses of $20.6 million in 2025 with an accumulated deficit of $97.1 million. The company relies entirely on its sole approved commercial product, ZUNVEYL.
Filed Mar 31, 2026 - FY2024 10-K risk factors75 risks
Alpha Cognition relies heavily on the commercial success of its sole FDA-approved drug, ZUNVEYL.
Filed Mar 31, 2025